Avalo Therapeutics
Open
$14.32
Prev. Close
$14.30
High
$14.38
Low
$14.32
Market Snapshot
$326.56M
-3.9
-31.72
$441K
33
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Wayne, Pennsylvania and currently employs 33 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Wayne, Pennsylvania and currently employs 33 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Recently from Cashu
Avalo Therapeutics Shows Strong Financial Performance and Growth Potential in Biopharmaceutical Market
Avalo Therapeutics Inc (NASDAQ:AVTX) continues to exhibit promising growth potential within the biopharmaceutical sector, as indicated by its recent first-quarter financial results. The company report…
Avalo Therapeutics Advances Genetic Medicine with Innovative Therapies for Rare Diseases
Innovative Advances in Genetic Medicine: Avalo Therapeutics' Pioneering Research Avalo Therapeutics makes notable strides in genetic medicine with its proprietary approach to developing therapies for…
Avalo Therapeutics Makes Progress in Gene Therapy for Rare Genetic Disorders
Avalo Therapeutics Advances Gene Therapy Research Avalo Therapeutics has made significant strides in the field of gene therapy by advancing its research focused on rare genetic disorders. The company’…